Attention Training for COVID-19 Related Distress

Anxiety Clinical Trial

Official title:

Attention Training for COVID-19 Related Distress

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06267313
• Other study ID #: 2023-078-PAU
• Status: Recruiting
• Phase: N/A
• Start date: February 19, 2024
• Est. completion date: February 19, 2027

Study information

• Verified date: April 2024
• Source: Palo Alto University
• Contact: Mikael Rubin, PhD
• Phone: 650-433-3805
• Email: mrubin[@]paloaltou.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: February 19, 2027
• Est. primary completion date: February 19, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19 Anxiety Syndrome Scale > 7 and/or COVID-19 related loss

Exclusion Criteria:

• Does not speak English Fluently

Related Conditions & MeSH terms

• Anxiety

Intervention

Behavioral:
• Attention Bias Modification
Training attention away from threat
• Attention Control Training
Training attention control
• Neutral training
Attention training with Neutral stimuli

Locations

Country	Name	City	State
United States	Palo Alto University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Palo Alto University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	COVID-19 Anxiety Syndrome Scale	The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.	0 days
Primary	COVID-19 Anxiety Syndrome Scale	The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.	21 days
Primary	COVID-19 Anxiety Syndrome Scale	The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.	49 days
Primary	COVID-19 Anxiety Syndrome Scale	The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.	105 days